Literature DB >> 18356936

Identification of dysregulated genes in lymphocytes from children with Down syndrome.

Cesar A Sommer1, Erika C Pavarino-Bertelli, Eny M Goloni-Bertollo, Flavio Henrique-Silva.   

Abstract

The molecular mechanisms by which trisomy of human chromosome 21 disrupts normal development are not well understood. Global transcriptome studies attempting to analyze the consequences of trisomy in Down syndrome (DS) tissues have reported conflicting results, which have led to the suggestion that the analysis of specific tissues or cell types may be more productive. In the present study, we set out to analyze global changes of gene expression in lymphocytes from children with trisomy 21 by means of the serial analysis of gene expression (SAGE) methodology. Two SAGE libraries were constructed using pooled RNA of normal and Down syndrome children. Comparison between DS and normal profiles revealed that most of the transcripts were expressed at similar levels and functional classes of abundant genes were equally represented. Among the 242 significantly differentially expressed SAGE tags, several transcripts downregulated in DS code for proteins involved in T-cell and B-cell receptor signaling (e.g., PI3Kdelta, RGS2, LY6E, FOS, TAGAP, CD46). The SAGE data and interindividual variability were validated by real-time quantitative PCR. Our results indicate that trisomy 21 induces a modest dysregulation of disomic genes that may be related to the immunological perturbations seen in DS.

Entities:  

Mesh:

Year:  2008        PMID: 18356936     DOI: 10.1139/g07-100

Source DB:  PubMed          Journal:  Genome        ISSN: 0831-2796            Impact factor:   2.166


  17 in total

Review 1.  RNA-Seq and human complex diseases: recent accomplishments and future perspectives.

Authors:  Valerio Costa; Marianna Aprile; Roberta Esposito; Alfredo Ciccodicola
Journal:  Eur J Hum Genet       Date:  2012-06-27       Impact factor: 4.246

2.  Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes.

Authors:  Mireia Vilardell; Axel Rasche; Anja Thormann; Elisabeth Maschke-Dutz; Luis A Pérez-Jurado; Hans Lehrach; Ralf Herwig
Journal:  BMC Genomics       Date:  2011-05-11       Impact factor: 3.969

3.  Spatial organization of chromosome territories in the interphase nucleus of trisomy 21 cells.

Authors:  Stephan Kemeny; Christophe Tatout; Gaelle Salaun; Céline Pebrel-Richard; Carole Goumy; Natasha Ollier; Eugenie Maurin; Bruno Pereira; Philippe Vago; Laetitia Gouas
Journal:  Chromosoma       Date:  2017-12-14       Impact factor: 4.316

4.  The intellectual disability of trisomy 21: differences in gene expression in a case series of patients with lower and higher IQ.

Authors:  André Mégarbané; Florian Noguier; Samantha Stora; Laurent Manchon; Clotilde Mircher; Roman Bruno; Nathalie Dorison; Fabien Pierrat; Marie-Odile Rethoré; Bernadette Trentin; Aimé Ravel; Marine Morent; Gerard Lefranc; David Piquemal
Journal:  Eur J Hum Genet       Date:  2013-02-20       Impact factor: 4.246

Review 5.  Uncovering the complexity of transcriptomes with RNA-Seq.

Authors:  Valerio Costa; Claudia Angelini; Italia De Feis; Alfredo Ciccodicola
Journal:  J Biomed Biotechnol       Date:  2010-06-27

6.  Massive-scale RNA-Seq analysis of non ribosomal transcriptome in human trisomy 21.

Authors:  Valerio Costa; Claudia Angelini; Luciana D'Apice; Margherita Mutarelli; Amelia Casamassimi; Linda Sommese; Maria Assunta Gallo; Marianna Aprile; Roberta Esposito; Luigi Leone; Aldo Donizetti; Stefania Crispi; Monica Rienzo; Berardo Sarubbi; Raffaele Calabrò; Marco Picardi; Paola Salvatore; Teresa Infante; Piergiuseppe De Berardinis; Claudio Napoli; Alfredo Ciccodicola
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

7.  Domains of genome-wide gene expression dysregulation in Down's syndrome.

Authors:  Audrey Letourneau; Federico A Santoni; Ximena Bonilla; M Reza Sailani; David Gonzalez; Jop Kind; Claire Chevalier; Robert Thurman; Richard S Sandstrom; Youssef Hibaoui; Marco Garieri; Konstantin Popadin; Emilie Falconnet; Maryline Gagnebin; Corinne Gehrig; Anne Vannier; Michel Guipponi; Laurent Farinelli; Daniel Robyr; Eugenia Migliavacca; Christelle Borel; Samuel Deutsch; Anis Feki; John A Stamatoyannopoulos; Yann Herault; Bas van Steensel; Roderic Guigo; Stylianos E Antonarakis
Journal:  Nature       Date:  2014-04-17       Impact factor: 49.962

8.  Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia.

Authors:  Mariela Valle; Sharon E Plon; Karen R Rabin
Journal:  Leuk Res       Date:  2008-08-20       Impact factor: 3.156

9.  Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome.

Authors:  Cherie N Billingsley; Jared R Allen; Douglas D Baumann; Samantha L Deitz; Joshua D Blazek; Abby Newbauer; Andrew Darrah; Brad C Long; Brandon Young; Mark Clement; R W Doerge; Randall J Roper
Journal:  Am J Med Genet A       Date:  2013-07-10       Impact factor: 2.802

Review 10.  Molecular genetic analysis of Down syndrome.

Authors:  David Patterson
Journal:  Hum Genet       Date:  2009-06-13       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.